QURE - ユニキュア （uniQure N.V.）

The following slide deck was published by uniQure N.V.

A Relative Strength Rating upgrade for uniQure shows improving technical performance. Will it continue?

uniQure press release (QURE): FY GAAP EPS of -$2.71 beats by $0.98.Revenue of $106.48M (-79.7% Y/Y) beats by $83.27M.As of December 31, 2022, the Company had cash and cash…

~ Achieved U.S. and European Commission marketing approvals of first and only gene therapyfor adults with hemophilia B ~ ~ Advancing development of AMT-130 for patients with Huntington''s disease - …

~ Achieved U.S. and European Commission marketing approvals of first and only gene therapy for adults with hemophilia B ~

Potential U.S. and European approvals possible of etranacogene dezaparvovec for treatment of Hemophilia B before end of 2022 and early 2023 respectively.

At the close of the New York Stock Exchange, the Dow Jones rose 0.09%, the S&P 500 fell 0.12%, and the NASDAQ Composite fell 0.10%. The leading performer among the components of the Dow Jones index today was Walt Disney Company, which gained 2.48 points or 2.33% to close at 109.11. Quotes Dow Inc rose by 0.66 points (1.28%), ending trading at 52.15. Walgreens Boots Alliance Inc rose 0.49 points or 1.26% to close at 39.48. The biggest losers were JPMorgan Chase & Co, which shed 1.41 points or 1.22% to end the session at 114.35. Visa Inc Class A was up 2.55 points (1.18%) to close at 213.32, while McDonald''s Corporation was down 2.43 points (0.94%) to close at 256. .80. Leading gainers among the S&P 500 index components in today''s trading were Penn National Gaming Inc, which rose 5.56% to hit 36.05, Gap Inc, which gained 5.44% to close at 10.27, and also shares of General Motors Company, which rose 4.16% to close the session at 37.56. The biggest losers were Tyson Foods Inc, which shed 8.40% to close at 80.10.

The company is temporarily delaying higher-dose procedures of experimental gene therapy AMT-130.

Tucked in its Q2 earnings release , UniQure N.V. (NASDAQ: QURE ) said that in July, it had observed suspected, unexpected severe adverse reactions (SUSARs) in two patients after they were treated with the "higher dose" of AMT-130 in a European Phase 1b/2 trial. AMT-130 is a gene therapy candidate for Huntington''s disease. A third patient treated back in … Full story available on Benzinga.com

CinCor Pharma CINC +66%. Karuna Therapeutics KRTX +61%. Reata Pharmaceuticals RETA -31%. uniQure QURE -23%.

uniQure press release (QURE): Q1 GAAP EPS of -$1.00 misses by $0.20.Revenue of $1.79M (+297.8% Y/Y) misses by $0.67M.As of March 31, 2022, the Company had cash and cash equivalents…

~ Partner CSL Behring submitted Marketing Authorization Application (MAA) in Europe for etranacogene dezaparvovec in hemophilia B; MAA validated by the European Medicines Agency (EMA) and granted accelerated assessment ~

In last trading session, uniQure N.V. (NASDAQ:QURE) saw 0.48 million shares changing hands with its beta currently measuring 1.05. Company’s recent per share price level of $14.94 trading at -$0.52 or -3.36% at ring of the bell on the day assigns it a market valuation of $749.09M. That closing price of QURE’s stock is at … uniQure N.V. (NASDAQ:QURE) Drops -3.36%, But A Strong Recovery May Be Imminent Read More »

The European Medicines Agency accepted a marketing authorization application by CSL''s (CSLLY) unit CSL Behring''s for gene therapy etranacogene dezaparvovec (EtranaDez) to treat…